DMRA Damora Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Damora Therapeutics Inc reported revenue of n/a, net income of −$31.2M and diluted EPS of −$0.39; for the fiscal year ended December 2025 revenue was n/a.
DMRA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$211M, net income −$210M (margin n/a), EPS $3.98
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$22.3M, net income −$21.4M (margin n/a), EPS −$18.53
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$39.9M, net income −$38.3M (margin n/a), EPS −$36.08
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$61.2M, net income −$61.6M (margin n/a), EPS −$2.43
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$52.2M, net income −$51.8M (margin n/a), EPS −$2.05
DMRA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$31.2M, EPS −$0.39
- Quarter ended Mar 31, 2026: revenue n/a, net income −$27.8M, EPS −$0.62
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$201M, EPS $10.86
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.13M, EPS −$2.36
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.44M, EPS −$2.60
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.53M, EPS −$1.92
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.74M, EPS −$5.17
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.88M, EPS −$3.39
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.34M, EPS −$4.92
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.48M, EPS −$5.05
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$6.48M, EPS −$27.66
- Quarter ended Sep 30, 2023: revenue n/a, net income −$8.14M, EPS −$7.50
- Quarter ended Jun 30, 2023: revenue n/a, net income −$10.7M, EPS −$0.41
- Quarter ended Mar 31, 2023: revenue n/a, net income −$13.0M, EPS −$0.51
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$14.1M, EPS −$0.55
- Quarter ended Sep 30, 2022: revenue n/a, net income −$13.7M, EPS −$0.54
- Quarter ended Jun 30, 2022: revenue n/a, net income −$16.9M, EPS −$0.67
- Quarter ended Mar 31, 2022: revenue n/a, net income −$16.9M, EPS −$0.67
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$13.4M, EPS −$0.53
- Quarter ended Sep 30, 2021: revenue n/a, net income −$12.7M, EPS −$0.50
DMRA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.73M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow −$18.6M, share buybacks n/a, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow −$36.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$42.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$52.3M, share buybacks n/a, dividends $0.00 per share
DMRA balance sheet
- Jun 30, 2026: cash $541M, total assets $544M, total liabilities $27.6M, shareholders' equity $516M
- Mar 31, 2026: cash $533M, total assets $535M, total liabilities $23.8M, shareholders' equity $512M
- Dec 31, 2025: cash $258M, total assets $261M, total liabilities $20.1M, shareholders' equity $240M
- Sep 30, 2025: cash $7.61M, total assets $10.7M, total liabilities $2.73M, shareholders' equity $8.01M
- Jun 30, 2025: cash $10.2M, total assets $13.7M, total liabilities $2.74M, shareholders' equity $11.0M
- Mar 31, 2025: cash $11.9M, total assets $15.4M, total liabilities $1.66M, shareholders' equity $13.7M
- Dec 31, 2024: cash $14.2M, total assets $17.1M, total liabilities $1.30M, shareholders' equity $15.8M
- Sep 30, 2024: cash $19.7M, total assets $23.4M, total liabilities $2.44M, shareholders' equity $20.9M
Is DMRA profitable?
No. Damora Therapeutics Inc lost $263M over the last four quarters.
What is DMRA's EPS?
Diluted earnings per share over the last four quarters were $7.49; −$0.39 in the latest quarter.